| __timestamp | Iovance Biotherapeutics, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 381287000 |
| Thursday, January 1, 2015 | 12390000 | 452612000 |
| Friday, January 1, 2016 | 25602000 | 316800000 |
| Sunday, January 1, 2017 | 21262000 | 330100000 |
| Monday, January 1, 2018 | 28430000 | 265800000 |
| Tuesday, January 1, 2019 | 40849000 | 336200000 |
| Wednesday, January 1, 2020 | 60210000 | 423900000 |
| Friday, January 1, 2021 | 83664000 | 467000000 |
| Saturday, January 1, 2022 | 104097000 | 487000000 |
| Sunday, January 1, 2023 | 106916000 | 477100000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, United Therapeutics Corporation and Iovance Biotherapeutics, Inc. have demonstrated contrasting strategies in optimizing these costs.
From 2014 to 2023, United Therapeutics consistently maintained higher SG&A expenses, peaking at approximately $487 million in 2022. This reflects their expansive operational scale and robust market presence. In contrast, Iovance Biotherapeutics, with a more focused approach, saw their SG&A expenses grow from around $9 million in 2014 to over $107 million in 2023, marking a significant increase of over 1000%.
While United Therapeutics' expenses are nearly ten times that of Iovance, the latter's rapid growth suggests a strategic investment in scaling operations. This comparison highlights the diverse approaches within the biotech sector, where both expansion and efficiency play pivotal roles in financial strategy.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Verona Pharma plc
United Therapeutics Corporation vs Ultragenyx Pharmaceutical Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc
Analyzing Cost of Revenue: United Therapeutics Corporation and Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Geron Corporation
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?